-
60 8.03
Prognostic Impact of Pre-Transplant Measurable Residual Disease in Acute Myeloid Leukemia: A Bayesian Meta-Analysis of Contemporary Allogeneic Hematopoietic Cell Transplantation Cohorts
-
54 7.17
Therapeutic Architecture Rather Than Population Differences Drives Front-Line Outcomes in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Comparison-Specific Pooled Analysis of Rituximab-Era Cohorts
-
55 6.4
Differential Toxicity Patterns with Bispecific Antibody Monotherapy and Daratumumab-Based Combinations in Multiple Myeloma - A Pooled Analysis